CD177 and COVID-19: Since, COVID-19 was established a few days ago, to utilize the similar cell surface receptor ACE2 against SARS-CoV-1 [28,29], it might be hypothesized that CQ could potentially inhibit the glycosylation of the ACE2 receptor and thus could prevent the COVID-19 or SARS-CoV-2 binding to the targeted cells.